Evidence map›Paper›PMID 31408457›Full record

ArticlePloS one2019

Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo.

Kathleen M McAvoy, Hameetha Rajamohamed Sait, Galina Marsh, Michael Peterson, Taylor L Reynolds, Jake Gagnon, Sarah Geisler, Prescott Leach, Chris Roberts, Ellen Cahir-McFarland and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. BIN1Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kathleen M McAvoyBiogen, Cambridge, MA, United States of America.
Hameetha Rajamohamed SaitBiogen, Cambridge, MA, United States of America.
Galina MarshBiogen, Cambridge, MA, United States of America.
Michael PetersonBiogen, Cambridge, MA, United States of America.
Taylor L ReynoldsBiogen, Cambridge, MA, United States of America.
Jake GagnonBiogen, Cambridge, MA, United States of America.
Sarah GeislerBiogen, Cambridge, MA, United States of America.
Prescott LeachBiogen, Cambridge, MA, United States of America.
Chris RobertsBiogen, Cambridge, MA, United States of America.
Ellen Cahir-McFarlandBiogen, Cambridge, MA, United States of America.
Richard M RansohoffDepartment of Cell Biology, Harvard Medical School, Boston, MA, United States of America.
Andrea CrottiBiogen, Cambridge, MA, United States of America.ORCID 0000-0002-9421-4370
Biogen (United States) · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BIN1 is the most important risk locus for Late Onset Alzheimer's Disease (LOAD), after ApoE. BIN1 AD-associated SNPs correlate with Tau deposition as well as with brain atrophy. Furthermore, the level of neuronal-specific BIN1 isoform 1 protein is decreased in sporadic AD cases in parallel with neuronal loss, despite an overall increase in BIN1 total mRNA. To address the relationship between reduction of BIN1 and neuronal cell loss in the context of Tau pathology, we knocked-down endogenous murine Bin1 via stereotaxic injection of AAV-Bin1 shRNA in the hippocampus of mice expressing Tau P301S (PS19). We observed a statistically significant reduction in the number of neurons in the hippocampus of mice injected with AAV-Bin1 shRNA in comparison with mice injected with AAV control. To investigate whether neuronal loss is due to deletion of Bin1 selectively in neurons in presence Tau P301S, we bred Bin1flox/flox with Thy1-Cre and subsequently with PS19 mice. Mice lacking neuronal Bin1 and expressing Tau P301S showed increased mortality, without increased neuropathology, when compared to neuronal Bin1 and Tau P301S-expressing mice. The loss of Bin1 isoform 1 resulted in reduced excitability in primary neurons in vitro, reduced neuronal c-fos expression as well as in altered microglia transcriptome in vivo. Taken together, our data suggest that the contribution of genetic variation in BIN1 locus to AD risk could result from a cell-autonomous reduction of neuronal excitability due to Bin1 decrease, exacerbated by the presence of aggregated Tau, coupled with a non-cell autonomous microglia activation.

Indexed as

Disease Models, AnimalAdaptor Proteins, Signal TransducingAlzheimer DiseaseAnimalsBehavior, AnimalBiomarkersBrainFemaleGene Expression ProfilingHippocampusMaleMiceMice, Inbred C57BLMice, KnockoutNerve Tissue ProteinsNeuronsAdaptor Proteins, Signal TransducingBin1 protein, mouseBiomarkersNerve Tissue Proteinstau ProteinsTumor Suppressor Proteins

Identifiers

PMID31408457
PMCPMC6692034
OpenAlexW2968451481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.